810 related articles for article (PubMed ID: 15184499)
41. Suppression of alloimmunity in mice by regulatory T cells converted with conditioned media.
Teng L; Liu L; Su Y; Yuan X; Li J; Fu Q; Chen S; Wang C
J Surg Res; 2011 Dec; 171(2):797-806. PubMed ID: 20538297
[TBL] [Abstract][Full Text] [Related]
42. Deficiency in NOD antigen-presenting cell function may be responsible for suboptimal CD4+CD25+ T-cell-mediated regulation and type 1 diabetes development in NOD mice.
Alard P; Manirarora JN; Parnell SA; Hudkins JL; Clark SL; Kosiewicz MM
Diabetes; 2006 Jul; 55(7):2098-105. PubMed ID: 16804081
[TBL] [Abstract][Full Text] [Related]
43. [Infusion of ex vivo expanded homologous CD4⁺;CD25⁺; regulatory T cells promotes the susceptibility to tumor in mice].
Guo T; Luo S; Xu J; Dai J; Liu Z; Gao X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 May; 30(5):466-70. PubMed ID: 24796739
[TBL] [Abstract][Full Text] [Related]
44. Therapeutic potential of self-antigen-specific CD4+ CD25+ regulatory T cells selected in vitro from a polyclonal repertoire.
Fisson S; Djelti F; Trenado A; Billiard F; Liblau R; Klatzmann D; Cohen JL; Salomon BL
Eur J Immunol; 2006 Apr; 36(4):817-27. PubMed ID: 16525991
[TBL] [Abstract][Full Text] [Related]
45. Pro-apoptotic DNA vaccination ameliorates new onset of autoimmune diabetes in NOD mice and induces foxp3+ regulatory T cells in vitro.
Li A; Ojogho O; Franco E; Baron P; Iwaki Y; Escher A
Vaccine; 2006 Jun; 24(23):5036-46. PubMed ID: 16621191
[TBL] [Abstract][Full Text] [Related]
46. Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice.
Elinav E; Waks T; Eshhar Z
Gastroenterology; 2008 Jun; 134(7):2014-24. PubMed ID: 18424268
[TBL] [Abstract][Full Text] [Related]
47. Essential roles of TGF-beta in anti-CD3 antibody therapy: reversal of diabetes in nonobese diabetic mice independent of Foxp3+CD4+ regulatory T cells.
Chen G; Han G; Wang J; Wang R; Xu R; Shen B; Qian J; Li Y
J Leukoc Biol; 2008 Feb; 83(2):280-7. PubMed ID: 18029395
[TBL] [Abstract][Full Text] [Related]
48. In-vitro generation and characterisation of murine CD4+CD25+ regulatory T cells with indirect allospecificity.
Tsang J; Jiang S; Tanriver Y; Leung E; Lombardi G; Lechler RI
Int Immunopharmacol; 2006 Dec; 6(13-14):1883-8. PubMed ID: 17161341
[TBL] [Abstract][Full Text] [Related]
49. Functional and molecular comparison of anergic and regulatory T lymphocytes.
Knoechel B; Lohr J; Zhu S; Wong L; Hu D; Ausubel L; Abbas AK
J Immunol; 2006 Jun; 176(11):6473-83. PubMed ID: 16709804
[TBL] [Abstract][Full Text] [Related]
50. Interleukin-10 limits the expansion of immunoregulatory CD4-CD8- T cells in autoimmune-prone non-obese diabetic mice.
Hillhouse EE; Beauchamp C; Chabot-Roy G; Dugas V; Lesage S
Immunol Cell Biol; 2010; 88(8):771-80. PubMed ID: 20603635
[TBL] [Abstract][Full Text] [Related]
51. CD4+ CD25+ regulatory T cell repertoire formation in response to varying expression of a neo-self-antigen.
Lerman MA; Larkin J; Cozzo C; Jordan MS; Caton AJ
J Immunol; 2004 Jul; 173(1):236-44. PubMed ID: 15210780
[TBL] [Abstract][Full Text] [Related]
52. BDC12-4.1 T-cell receptor transgenic insulin-specific CD4 T cells are resistant to in vitro differentiation into functional Foxp3+ T regulatory cells.
Sarikonda G; Fousteri G; Sachithanantham S; Miller JF; Dave A; Juntti T; Coppieters KT; von Herrath M
PLoS One; 2014; 9(11):e112242. PubMed ID: 25393309
[TBL] [Abstract][Full Text] [Related]
53. Glutamic acid decarboxylase-derived epitopes with specific domains expand CD4(+)CD25(+) regulatory T cells.
Chen G; Han G; Feng J; Wang J; Wang R; Xu R; Shen B; Qian J; Li Y
PLoS One; 2009 Sep; 4(9):e7034. PubMed ID: 19759824
[TBL] [Abstract][Full Text] [Related]
54. Stem cell-derived tissue-associated regulatory T cells suppress the activity of pathogenic cells in autoimmune diabetes.
Haque M; Lei F; Xiong X; Das JK; Ren X; Fang D; Salek-Ardakani S; Yang JM; Song J
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30777937
[TBL] [Abstract][Full Text] [Related]
55. Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen.
Knoechel B; Lohr J; Kahn E; Bluestone JA; Abbas AK
J Exp Med; 2005 Nov; 202(10):1375-86. PubMed ID: 16287710
[TBL] [Abstract][Full Text] [Related]
56. Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells.
Bluestone JA; Tang Q
Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14622-6. PubMed ID: 15322272
[TBL] [Abstract][Full Text] [Related]
57. Regulation of Diabetogenic Immunity by IL-15-Activated Regulatory CD8 T Cells in Type 1 Diabetes.
Stocks BT; Wilson CS; Marshall AF; Hoopes EM; Moore DJ
J Immunol; 2019 Jul; 203(1):158-166. PubMed ID: 31127035
[TBL] [Abstract][Full Text] [Related]
58. Proinsulin multi-peptide immunotherapy induces antigen-specific regulatory T cells and limits autoimmunity in a humanized model.
Gibson VB; Nikolic T; Pearce VQ; Demengeot J; Roep BO; Peakman M
Clin Exp Immunol; 2015 Dec; 182(3):251-60. PubMed ID: 26206289
[TBL] [Abstract][Full Text] [Related]
59. Killer cell Ig-like receptor (KIR) 3DL1 down-regulation enhances inhibition of type 1 diabetes by autoantigen-specific regulatory T cells.
Qin H; Wang Z; Du W; Lee WH; Wu X; Riggs AD; Liu CP
Proc Natl Acad Sci U S A; 2011 Feb; 108(5):2016-21. PubMed ID: 21245333
[TBL] [Abstract][Full Text] [Related]
60. Immunomodulation Followed by Antigen-Specific T
Cabello-Kindelan C; Mackey S; Sands A; Rodriguez J; Vazquez C; Pugliese A; Bayer AL
Diabetes; 2020 Feb; 69(2):215-227. PubMed ID: 31712320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
